Dr. Rini Mohan Palathingal, MD

Dr. Palathingal practices at Englewood Hospital in Englewood, New Jersey, part of RWJBarnabas Health.

Dr. Palathingal's NPI, 1255440962, was assigned on August 29, 2006. Dr. Palathingal holds New Jersey license MA071128.

Dr. Palathingal's primary practice is Englewood Hospital, at 350 Engle St, Englewood, NJ 07631 in Bergen County. The practice phone is (201) 894-3000.

Dr. Palathingal's primary practice is Englewood Hospital in Englewood, New Jersey, part of RWJBarnabas Health. Dr. Palathingal is also affiliated with Jersey City Medical Center. The medical group on file is Medical Associates at Englewood. Dmand AI also links Dr. Palathingal to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palathingal practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Palathingal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Palathingal is licensed in New Jersey.

CMS data shows 1,838 Medicare services from Dr. Palathingal across 10 procedure codes in 2024, for 248 Medicare patients. Medicare paid $111,529 for them. Every service was in an office.

CMS counts 248 Medicare patients who saw Dr. Palathingal in 2024. The largest group is 75 to 84, with 93 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Palathingal's median patient age at 70, with 72% women.

In 2024, Dr. Palathingal wrote 924 Medicare Part D claims for 156 patients. 71% of them were for generic drugs. CMS names the drug for 621 of them, across 30 drugs with 11 or more claims each, at $3,193,721 in total drug cost. In 2023, CMS named 554 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Palathingal for performance year 2024, reported through an alternative payment model (APM). Dr. Palathingal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Palathingal as offering telehealth.

CMS Open Payments shows 953 general payments to Dr. Palathingal from 68 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 84% of the total. Novartis Pharmaceuticals Corporation paid the most, $3,512.